SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Steve Lokness who wrote (265)3/22/1998 11:20:00 PM
From: Boyce Burge  Read Replies (2) of 4474
 
Im a little vague myself, but its basically a suite of genes that could be introduced into an embryonic cell and eventually find itself in most cells or every cell of an organism. It could be turned on or off by a small molecule and could control such events as aging-related changes, or whatever can be controlled by an introduced gene. Though this is pie in the sky today as far as humans go, it is very feasible in animal models and in fact there was a conference on the subject at UCLA this weekend.

ARIAs strategy for turning on or off introduced genes is similar to this germline-cassete concept, although not currently targeted at germ cells (not yet!). You will have to hold your ARIA shares for a long time to see the $$ benefits of this, I'm afraid.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News